Digestive Care, Inc. announces expansion of manufacturing facility

May 16, 2007 — /PRNewswire/ — BETHLEHEM, PA — Digestive Care, Inc (DCI) announced today that it is quadrupling the capacity of its manufacturing, research and development facility in order to meet the growing demand for PANCRECARB(R) (pancrelipase), a pancreatic enzyme for the treatment of pancreatic insufficiency.

“This expansion is essential to ensuring that there is ample supply of PANCRECARB(R) for patients whose lives are dependent on the availability of this medication,” said Dr. Tibor Sipos, president and founder of DCI. “Our continued success is a result of PANCRECARB(R)’s market acceptance and an outstanding multidisciplinary team entirely dedicated to providing support to healthcare providers and patients.”

The PANCRECARB(R) expanded manufacturing and research facility, located in Bethlehem, PA, will also enable DCI to research, develop, and manufacture other therapeutic products, including those for managing digestive disorders associated with cystic fibrosis and cholestatic liver diseases.

PANCRECARB(R) is an exocrine pancreatic insufficiency drug product. It is the only enteric coated and bicarbonate buffered pancreatic enzyme which is protected by several U.S. patents. In April 2004, the FDA determined that prescription exocrine pancreatic insufficiency drug products are medically necessary and, accordingly, allowed the drug manufacturers four years (April 2008) to obtain approved new drug applications. PANCRECARB(R) is on track to fulfill these requirements.

About Digestive Care, Inc.
DCI is dedicated to developing unique pharmaceutical products to alleviate complications and symptoms of gastrointestinal disorders. DCI was founded in 1990. The company holds 15 U.S. and foreign patents and has a national distribution network. The Company’s technology is based on the ability to commercially develop unique drug delivery systems for delivering bioactive molecules to their target site. DCI’s research into the controlled delivery of gastric acid resistant digestive enzymes and buffered bile acids through micro encapsulation led to the development of the highly successful drug product, PANCRECARB(R) (pancrelipase).

Source: Digestive Care, Inc.

Maggi Campbell of Digestive Care, Inc.,
Tel:+1-610-882-5950 (office)
Email: [email protected]
Web site: http://www.digestivecare.com/


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.